Logo
MESOHEAL+ 2.5ml x 5 syringes

MESOHEAL+ 2.5ml x 5 syringes

Mesoheal

Injectable skin booster / biorevitalisation
  • Manufactured by Koru Pharma Co., Ltd., a South Korean biopharmaceutical company specialising in medical aesthetic products and skin boosters.
  • Marketed internationally as an injectable biorevitalisation skin booster and, in some contexts, as a medical device or dermal injectable; it is not listed as a licensed medicinal product with the UK MHRA.
  • Intended only for professional use in accordance with local laws, medical device or medicinal Product regulations and clinic governance.
  • Clinics and practitioners using MESOHEAL+ are expected to comply with relevant injection safety standards, infection control protocols and professional licensing requirements in their jurisdiction.
Non-cross-linked hyaluronic acid mesotherapy (sodium hyaluronate skin booster)

Description

MESOHEAL+ is an advanced biorevitalisation solution developed by Koru Pharma for professional intradermal use. It contains high molecular weight, non-cross-linked sodium hyaluronate (hyaluronic acid) at a concentration of 25 mg in a 2.5 ml prefilled syringe. The product is designed to improve skin quality by providing deep hydration, stimulating fibroblast activity and supporting the synthesis of endogenous collagen and elastin. MESOHEAL+ injections are used by trained medical professionals to revitalise tired, dehydrated or photo-aged skin, smooth fine lines and wrinkles, improve elasticity and viscoelasticity, regulate melanogenesis and support the management of conditions such as rosacea and hyperpigmentation. In addition to aesthetic indications for the face and body, MESOHEAL+ is also described by the manufacturer as suitable for selected joint treatments under medical supervision. Each box contains five sterile, single-use 2.5 ml syringes intended strictly for professional use in clinical or aesthetic practice.

Bnefits

  • Provides rapid, visible skin rejuvenation and hydration through high molecular weight, non-cross-linked hyaluronic acid.
  • Delivers immediate and long-lasting moisturisation of the skin, reducing dryness and flaking.
  • Improves skin elasticity, firmness and overall viscoelasticity by stimulating fibroblast activity and supporting collagen and elastin synthesis.
  • Reduces the appearance of fine lines and wrinkles and helps to smooth overall skin texture and tone.
  • Helps to regulate melanogenesis, supporting the management of hyperpigmentation and uneven skin tone.
  • Supports elimination of skin inflammation and improves sebaceous gland function, which can benefit breakout-prone or rosacea-prone skin.
  • Shrinks the appearance of enlarged pores and promotes a tighter, more lifted-looking skin surface.
  • Non-cross-linked HA formulation can be used for both aesthetic skin biorevitalisation and, under doctor supervision, selected joint applications.

Indications

  • Derma dehydration and chronically dry or dull skin.
  • Rugulose type of ageing and fine surface wrinkling.
  • Expression lines and early static wrinkles on the face.
  • Photo-ageing and chrono-ageing with reduced elasticity and firmness.
  • Sagging or fading skin on the face, neck and décolleté.
  • Hyperpigmentation and uneven skin tone, including pigmentation after sun exposure.
  • Dehydrated skin after sunbathing, solarium use or exposure to low temperatures.
  • Symptoms of rosacea and skin prone to inflammatory flare-ups (for use by medical professionals).
  • Sebaceous gland dysfunction and clinical evidence of acneiform rash, where normalisation of oil gland activity and barrier repair are desired.
  • Preparation of tissues before contour plastic surgery or thread lifting procedures.
  • Supportive treatment during preparation and rehabilitation phases around plastic surgeries and medium to deep exfoliation procedures.
  • Selected joint-related indications (such as arthrosis/arthritis and intra-articular lubrication) when used under the direction of a medical doctor, as described by the manufacturer.

Composition

  • Active ingredient: Sodium hyaluronate (hyaluronic acid) – 25 mg per 2.5 ml syringe.
  • Type of hyaluronic acid: Non-cross-linked (non-stabilised), high molecular weight.
  • Nominal molecular weight of HA: ≥ 1,500 kDa (approximately 1500 kDa).
  • Presentation: Highly refined hyaluronic acid solution in sterile, prefilled syringes for intradermal or intra-articular injection.
  • Excipient: Sterile aqueous vehicle suitable for injectable hyaluronic acid (exact excipient composition not publicly detailed).

Formulation

  • Single-use prefilled syringe containing 2.5 ml of non-cross-linked sodium hyaluronate solution.
  • Each syringe contains 25 mg of high molecular weight hyaluronic acid (sodium hyaluronate).
  • Formulated as a viscoelastic, clear injectable solution intended for intradermal biorevitalisation.
  • High molecular weight HA is designed to provide strong hydration and create optimal conditions in the extracellular matrix for fibroblast activity and tissue regeneration.
  • Non-animal origin sodium hyaluronate produced via bacterial fermentation, according to the manufacturer.
  • Intended exclusively for administration by trained medical professionals in an appropriate clinical or aesthetic setting.

Packaging

  • 1 box containing 5 sterile prefilled syringes x 2.5 ml each.
  • Each syringe is individually packed and sterilised for single use only.
  • Outer carton branded MESOHEAL+ with product name and hyaluronic acid content (Sodium Hyaluronate 25 mg / 2.5 ml x 5).
  • Packaged for professional distribution via authorised medical and aesthetic suppliers.
  • Manufacturer origin: Republic of Korea; products distributed in multiple international markets, including the European Community (EC) through authorised partners.

Usage

  • For professional use only: MESOHEAL+ is intended exclusively for administration by qualified and appropriately trained medical professionals or aesthetic practitioners operating within local regulations.
  • Route of administration: intradermal injection into the superficial layers of the dermis in indicated treatment areas (and, where applicable, intra-articular administration under medical supervision).
  • Typical treatment areas for aesthetic use include the face, neck, décolleté, leg surface, lateral surface of the buttocks, upper limb girdle, dorsum of wrists and feet, anterior abdominal wall and other regions selected by the practitioner based on clinical judgment.
  • The course of therapy should always be individualised according to the patient’s skin condition, age, indication and overall health status, following the manufacturer’s professional protocol.
  • Manufacturer literature describes a basic treatment course consisting of multiple procedures spaced at intervals of approximately 10–14 days over several months, followed by maintenance (supportive) sessions as needed.
  • All injections must be performed under strict aseptic conditions, using appropriate medical devices and sharps disposal procedures, in compliance with local clinical and regulatory standards.
  • MESOHEAL+ must not be self-administered by patients or used as a home-treatment product.

Contraindications

  • Age under 18 years.
  • Pregnancy and lactation period.
  • Active skin infections or inflammatory skin diseases in the proposed treatment area.
  • Oncological (cancer) diseases.
  • Documented autoimmune diseases, as highlighted in manufacturer educational materials.
  • Known hypersensitivity or allergy to hyaluronic acid or any component of the formulation.
  • Any other condition for which injectable hyaluronic acid or invasive aesthetic procedures are contraindicated under local medical guidelines.
  • Use in patients who are not suitable candidates for minimally invasive aesthetic procedures as determined by the treating medical professional.

Adverse Effects

  • As with other intradermal or joint injections of hyaluronic acid, common transient reactions may include local swelling, redness, bruising, tenderness or discomfort at the injection site.
  • Temporary itching, mild inflammatory reactions or sensitivity in the treated areas can occur following treatment.
  • In rare cases, more pronounced inflammatory or hypersensitivity reactions may develop; these require medical assessment and management.
  • Improper injection technique or use by unqualified individuals may increase the risk of complications, including uneven correction, nodules, infection or other adverse outcomes.
  • The overall safety profile should be evaluated and monitored by the prescribing and injecting healthcare professional, taking into account each patient’s medical history.

Storage Conditions

  • Store sealed in the original packaging, protected from light and moisture.
  • Recommended storage temperature: typically 15–25°C as specified in the manufacturer’s product literature.
  • Do not freeze and do not expose to excessive heat or direct sunlight.
  • Keep out of reach of children.
  • Use only within the stated expiry date printed on the packaging and discard any damaged or compromised syringes in accordance with medical waste regulations.

Duration

Manufacturer guidance describes a basic treatment course of approximately 5\u20136 procedures performed every 10\u201314 days over about 3 months, followed by maintenance sessions once a month according to individual patient needs. The clinical effect on skin quality is generally reported to last around 6 months, varying with age, skin condition and lifestyle.

Onset

Described as quick and visible, with many patients experiencing noticeable improvement in skin hydration, texture and radiance shortly after the initial procedures, and further improvements in elasticity and wrinkle reduction over the course of treatment.

Browse more Injectable skin booster / biorevitalisation

Top Treatments

Top Cities in the UK